While new treatment strategies are being intensely studied, timely assessment of their efficacy has proven difficult. In a presentation today, Mitchell Machtay, MD, principal investigator of the ACRIN 6668/RTOG 0235 trial and RTOG deputy chair, reported the that post-treatment F-18 fluorodeoxyglucose-positron emission tomography (FDG-PET) scans show promise for predicting the prognosis of patients with inoperable disease.
"These results are encouraging," says Machtay. "Definitive prognostic information after a patient completes therapy has not been available for making decisions about further treatment options, and these preliminary results suggest that FDG-PET may play an important role in that regard."
Twenty ACRIN and RTOG participating sites enrolled 251 patients into the phase III trial that gathered pre- and post-treatment FDG-PET scans — treatment included both chemotherapy and radiation therapy. Specifically, investigators sought to determine if the standardized uptake value (SUV), a quantitative measure of how rapidly tumor cells are using the glucose-based FDG radiotracer, obtained on post-treatment FDG-PET scans was predictive of a patient's survival. As Machtay reported, "The post-treatment scan was predictive for patients' prognosis by identifying that patients with high levels of FDG uptake following treatment had more aggressive tumors that were more likely to recur, and the higher the SUV measure in the primary tumor, the greater the recurrence rate and the lower a patient's corresponding survival outlook."
"The results announced today suggest that FDG-PET has a role in helping physicians make more informed treatment decisions, such as starting a patient on a new chemotherapy program," says Barry Siegel, MD, ACRIN co-deputy chair and medical director of the ACR PET Imaging Core Laboratory, "and helping investigators determine whether a treatment regimen is worthy of further study before long-term survival data are available."
The FDG-PET scan results provided for this analysis were interpreted by physicians at the participating sites. Further analyses are ongoing evaluating scan data interpreted by central review at the ACR Imaging Core Laboratory and using other semi-quantitative measures.
The study is supported by the NCI: ACRIN grants U01 CA 079778 and CA080098, and RTOG grants U10 CA21661 and CA37422.
For interviews with an ACRIN or RTOG investigator, please contact Heather Curry at 703-390-9822 or PR@acr.org.
ACRIN, a member of the NCI Clinical Trials Cooperative Group program, is made up of investigators from over 100 academic and community-based facilities in the United States and abroad. ACRIN's oncology mission is to develop information through clinical trials of medical imaging with the potential to increase the length and quality of life of cancer patients. As recently announced, the oncology research agendas of ACRIN and the Eastern Cooperative Oncology Group are soon to be merged, with biomarker research as a central focus. ACRIN also carries out research through its cardiovascular and neuroscience committees. Its imaging core laboratory supports the imaging operations of the ACRIN enterprise as well as other organizations carrying out imaging research. ACRIN is headquartered at the ACR Clinical Research Center in Philadelphia, PA. The ACRIN Biostatistics Center is located at Brown University in Providence, RI. www.acrin.org
The Radiation Therapy Oncology Group (RTOG) is administered by the American College of Radiology (ACR) and located in the ACR Center for Clinical Research in Philadelphia, PA. RTOG is a multi-institutional, international clinical cooperative group funded primarily by National Cancer Institute grants CA21661, CA32115 and CA37422. RTOG has 40 years of experience in conducting clinical trials and is comprised of over 300 major research institutions in the United States, Canada and internationally. The group currently is currently accruing to 40 studies that involve radiation therapy alone or in conjunction with surgery and/or chemotherapeutic drugs or which investigate quality of life issues and their effects on the cancer patient. The American College of Radiology (ACR) is a national professional organization serving more than 32,000 radiologists, radiation oncologists, interventional radiologists and medical physicists with programs focusing on the practice of radiology and the delivery of comprehensive health care services.
Correct connections are crucial
26.06.2017 | Charité - Universitätsmedizin Berlin
One gene closer to regenerative therapy for muscular disorders
01.06.2017 | Cincinnati Children's Hospital Medical Center
19.06.2017 | Event News
13.06.2017 | Event News
13.06.2017 | Event News
26.06.2017 | Life Sciences
26.06.2017 | Physics and Astronomy
26.06.2017 | Information Technology